A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The kidney plays a central role in the regulation of plasma glucose levels. Glucose is freely filtered at the glomerulus and is normally reabsorbed via specific apical glucose transporters. In recent years, the identity of these transporters has been established. The sodium–glucose co-transporter type 2 (SGLT2) is a 672 amino acid high-capacity low-affinity transporter expressed in the S1 segment of the proximal tubule which is believed to mediate the majority of renal glucose reabsorption. The type 1 sodium–glucose co-transporter SGLT1, primarily expressed in the S3 segment of the proximal tubule and the small intestine, is a high-affinity, low-capacity glucose transporter saturated at or near physiological glucose concentrations [1]. SGLT1 has a 10-fold greater affinity for galactose and its deficiency is responsible for glucose–galactose malabsorption [2]. Primary renal glucosuria (OMIM #233100) is a disorder characterized by renal glucose wasting in the absence of hyperglycaemia or other proximal tubular dysfunction. Deficiency of SGLT2 recently has been shown to cause autosomal recessive renal glucosuria [3,4]. Here, we describe a patient with autosomal recessive renal glucosuria attributable to a homozygous mutation in SLC5A2. This case is unique in that our patient is quite healthy and fit at the age of 82. Her well-being clarifies the benign nature of SGLT2 deficiency, which has implications for the treatment of diabetes and obesity. The patient is an 82-year-old healthy woman, the second child of consanguineous Italian parents. Her parents were first cousins. The patient was first noted to have glucosuria in the absence of hyperglycaemia at the age of 6. Her past medical history is pertinent for hypertension diagnosed 1 year ago and pyelonephritis diagnosed 2 years ago. She has no history of diabetes, heart, lung, neurological or musculoskeletal diseases, and denies any history of hypoglycaemia. Repeated evaluation in the past failed to define the cause of her persistent glucosuria. To her knowledge, her parents, brothers, sisters, cousins and children have no history of glucosuria. The patient came to our attention recently. An extensive laboratory investigation revealed no abnormalities with the exception of glucosuria, which was quantitated at >30 g/day, with a fractional glucose excretion of 55%. In particular, there was no proteinuria, β-2 microglobulinuria, acidosis, hyperglycaemia, amino aciduria or phosphaturia. Creatinine clearance was 49 ml/min. A blood sample for DNA analysis was obtained from our index patient after she signed an informed written consent form, in accordance with institutional review board-approved protocols, and genomic DNA was extracted as described previously [5]. All coding exons and flanking intronic regions of SLC5A2 were amplified and sequenced directly using the previously described primers [3]. Sequence analysis of SLC5A2 genomic DNA in our patient revealed only one mutation: a homozygous substitution of two adenines for two guanines within exon 8 (G910A, G911A, numbered from the start codon) altering Gly304 to lysine (Figure 1A and B); the identified mutation in our patient was confirmed by repeat polymerase chain reaction (PCR) amplification and sequencing of the opposite strand. Of interest, we detected no heterozygosity in the >5000 bp we analysed, suggesting that the patient had inherited the identical allele from both parents due to the history of consanguinety in her family. We screened exon 8 in 180 control individuals whose DNA had been referred to our laboratory for evaluation of other genetic diseases; these individuals were primarily American of Caucasian descent with a small number of Hispanic-Americans as well. Using denaturing high-performance liquid chromatography (DHPLC) as described previously [6], we did not observe this allele in any other individuals (data not shown), indicating that the G304K mutation is not a common polymorphism. Sequence alteration in SLC5A2 in a patient with primary renal glucosuria. Genomic DNA sequence of the coding strand of exon 8 in SGLT2. (A) Sequence of the selected region of exon 8 in a wild-type individual. (B) Sequence of the same region of exon 8 in our index patient with primary glucosuria. Our patient has a homozygous substitution of adenines for guanines at the indicated position (nucleotides 910 and 911 numbered from the start codon) resulting in a substitution of lysine for glycine. (C and D) Conservation of G304 in SGLT2 in other species (C) and in related sodium–solute co-transporters in humans (D). The amino acid sequences of selected sodium–solute transporters were aligned using Clustal W [9], and the residues corresponding to Gly304 are highlighted. Members of the sodium–solute co-transporter family all have either glycine or the structurally similar alanine at this position. Previous studies have documented that patients heterozygous for disease-causing mutations in SLC5A2 may have elevated levels o
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease
Li, A., Davila, S., Furu, L., Qian, Q., Tian, X., Kamath, P. S., King, B. F., Torres, V. E., & Somlo, S. (2003) · The American Journal of Human Genetics · doi:10.1086/368295 · Cited by 193 · cited 1×
“Using denaturing high-performance liquid chromatography (DHPLC) as described previously [ 6 ], we did not observe this allele in any other individuals (data not shown), indicating that the G304K mutation is not a common polymorphism.”
Method
Cited by
Active sugar transport in health and disease
Wright, E. M., Hirayama, B. A., & Loo, D. F. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01746.x · Cited by 627
SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
Vallon, V., Platt, K. A., Cunard, R., Schroth, J., Whaley, J., Thomson, S. C., Koepsell, H., & Rieg, T. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010030246 · Cited by 563
Vallon, V., Gerasimova, M., Rose, M. A., Masuda, T., Satriano, J., Mayoux, E., Koepsell, H., Thomson, S. C., & Rieg, T. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00520.2013 · Cited by 483
“Available data in humans with 449 mutations in SGLT2 (SLC5A2), a rare and not well studied genetic disorder, indicate that no 450 other complications, including chronic nephrologic complications, are known to be consistently 451 associated with mutations of this gene (8; 16; 27; 29; 42).”
BackgroundKomoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.250 · Cited by 396
Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
Komoroski, B., Vachharajani, N., Boulton, D., Kornhauser, D., Geraldes, M., Li, L., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.251 · Cited by 350
Metadata
- Authors
- Francis, J.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-09-22
- Volume
- 19
- Issue
- 11
- Pages
- 2893-2895
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2115879800
- Cited by
- 47
- References
- 1
- FWCI
- 0.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. https://app.cochat.ai/papers/10.1093/ndt/gfh426
- The paper
- Francis, J. (2004). A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfh426
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.